P2X7 receptor antagonists: a patent review (2010–2015)

Expert Opinion on Therapeutic Patents

Volumn 27, Issue 3, 2017, Pages 257-267

  Park, Jin Hee ^a,b   Kim, Yong Chul ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b New Drug Development Center   (South Korea)

Author keywords

IL 1 ; ion channel; P2X7 receptor; Purinergic receptor

Indexed keywords

BIOLOGICAL PRODUCT; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2X7 RECEPTOR ANTAGONIST; PURINERGIC P2Y RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; PURINERGIC P2X RECEPTOR ANTAGONIST;

BIOLOGICAL ACTIVITY; DRUG INDUSTRY; DRUG STRUCTURE; HUMAN; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; DRUG DESIGN; DRUG EFFECTS; INFLAMMATION; METABOLISM; NEOPLASMS; PAIN; PATHOLOGY;

ANIMALS; DRUG DESIGN; HUMANS; INFLAMMATION; NEOPLASMS; PAIN; PATENTS AS TOPIC; PURINERGIC P2X RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2X7;

EID: 85011945260     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1080/13543776.2017.1246538     Document Type: Review

References (100)

1. North RA, Barnard EA., Nucleotide receptors. Curr Opin Neurobiol. 1997;7:346–357.
2. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50:413–492.
3. Surprenant A, Rassendren F, Kawashima E, et al. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science. 1996;272(5262):735–738.
4. Yu Y, Ugawa S, Ueda T, et al. Cellular localization of P2X7 receptor mRNA in the rat brain. Brain Res. 2008;1194:45–55.
5. Collo G, Neidhart S, Kawashima E, et al. Tissue distribution of the P2X7 receptor. Neuropharmacology. 1997;36(9):1277–1283.
6. Denlinger LC, Fisette PL, Sommer JA, et al. Cutting edge:the nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide. J Immunol. 2001;167(4):1871–1876.
7. Costa-Junior HM, Sarmento Vieira F, Coutinho-Silva R. C terminus of the P2X7 receptor:treasure hunting. Purinergic Signal. 2011;7(1):7–19.
8. Kawate T, Michel JC, Birdsong WT, et al. Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature. 2009;460(7255):592–598.
9. Hattori M, Gouaux E. Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature. 2012;485(7397):207–213.• The two articles reported the first crystal structure of zP2X4 receptor, which suggested the gating mechanism of the ion channel through binding of the natural agonist, ATP.
10. Alzola E, Pérez-Etxebarria A, et al. Activation by P2X7 agonists of two phospholipases A2 (PLA2) in ductal cells of rat submandibular gland. Coupling of the calcium-independent PLA2 with kallikrein secretion. J Biol Chem. 1998;273(46):30208–30217.
11. Pochet S, Gómez-Muñoz A, Marino A, et al. Regulation of phospholipase D by P2X7 receptors in submandibular ductal cells. Cell Signal. 2003;15(10):927–935.
12. Kahlenberg JM, Dubyak GR. Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am J Physiol Cell Physiol. 2004;286(5):C1100–8.
13. Donnelly-Roberts DL, Namovic MT, Faltynek CR, et al. Mitogen-activated protein kinase and caspase signaling pathways are required for P2X7 receptor (P2X7R)-induced pore formation in human THP-1 cells. J Pharmacol Exp Ther. 2004;308(3):1053–1061.
14. Korcok J, Raimundo LN, Ke HZ, et al. Extracellular nucleotides act through P2X7 receptors to activate NF-kappaB in osteoclasts. J Bone Miner Res. 2004;19(4):642–651.
15. Verhoef PA, Estacion M, Schilling W, et al. P2X7 receptor-dependent blebbing and the activation of rho-effector kinases, caspases, and IL-1 release. J Immunol. 2003;170:5728–5738.
16. Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. Embo J. 2006;25:5071–5082.
17. Locovei S, Scemes E, Qiu F, et al. Pannexin 1 is part of the pore forming unit of the P2X7 receptor death complex. FEBS Lett. 2007;581:483–488.
18. Iglesias R, Locovei S, Roque A, et al. P2X7 receptor-pannexin 1 complex:pharmacology and signaling. Am J Physiol Cell Physiol. 2008;295(3):C752–C760.
19. Alberto AV, Faria RX, Couto CGC, et al. Is pannexin the pore associated with the P2X7 receptor? Naunyn Schmiedebergs Arch Pharmacol. 2013;386(9):775–787.
20. Pelegrin P. Targeting Interleukin-1 signaling in chronic inflammation:focus on P2X7 receptor and Pannexin-1. Drug News Perspect. 2008;21:24–33.
21. Weber A, Wasiliew P, Kracht M, et al. Interleukin-1β (IL-1β) processing pathway. Sci Signal. 2010;19:CM2.
22. Ferrari D, Pizzirani C, Adinolfi E, et al. The P2X7 receptor:a key player in IL-1 processing and release. J Immunol. 2006;176:3877–3883.
23. Chessell IP, Hatcher JP, Bountra C, et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 2005;114:386–396.
24. Basso AM, Bratcher NA, Harris RR, et al. Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety:relevance for neuropsychiatric disorders. Behav Brain Res. 2009;198(1):83–90.
25. Csölle C, Andó RD, Kittel Á, et al. The absence of P2X7 receptors (P2rx7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice. Int J Neuropsychopharmacol. 2013;16(1):213–233.
26. Burnstock G, Di Virgilio F. Purinergic signalling and cancer. Purinergic Signal. 2013;9(4):491–540.• This is the review article regarding the roles of P2X7 receptor with cancers.
27. Ren S, Zhang Y, Wang Y, et al. Targeting P2X₇ receptor inhibits the metastasis of murine P388D1 lymphoid neoplasm cells to lymph nodes. Cell Biol Int. 2010;34(12):1205–1211.
28. Gu LQ, Li FY, Zhao L, et al. Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma. Endocrine. 2010;38(2):276–282.
29. Jelassi B, Anchelin M, Chamouton J, et al. Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors. Carcinogenesis. 2013;34(7):1487–1496.
30. Qiu Y, Li WH, Zhang H-Q, et al. P2X7 mediates ATP-driven invasiveness in prostate cancer cells. PLoS One. 2014;9(12):e114371.
31. Xia J, Yu X, Tang L, et al. P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway. Oncol Rep. 2015;34(1):103–110.
32. AZD9056. Bethesda MD:National Center for Advancing Translational Sciences (NCATS); 2011. Available from http://ncats.nih.gov/files/AZD9056.pdf
33. Keystone EC, Wang MM, Layton M, et al. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012;71(10):1630–1635.•• This article reported the results of phase IIa and IIb clinical studies of Astra Zeneca’s P2X7R targeted new drug candidate, AZD-9056 in the patients with rheumatoid arthritis.
34. Pfizer CE-224535/P2X7 Receptor Antagonist. Bethesda MD:National Center for Advancing Translational Sciences (NCATS); 2011. Available from https://ncats.nih.gov/files/CE-224535.pdf
35. Stock TC, Bloom BJ, Wei N, et al. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012;39(4):720–727.•• This article reported the results of phase IIa clinical study of Pfizer’s P2X7R targeted new drug candidate, CE-224,535 in the patients with rheumatoid arthritis.
36. Evotec grants exclusive rights on EVT 401 in China to conba pharmaceutical. United Kingdom:Evotec Ltd; 2012. Available from https://www.evotec.com/article/en/Press-releases/Evotec-grants-exclusive-rights-on-EVT-401-in-China-to-Conba-Pharmaceutical/2274
37. Studies filtered by compound GSK1482160. United Kingdom:GlaxoSmithKline plc; 2009. Available from http://www.gsk-clinicalstudyregister.com/compounds/gsk1482160#ps
38. AFC-5128. New York (NY):Torreya Insights, LLC; 2011. Available from http://www.avarx.com/search/showOpportunityDetails?asset_id=1440
39. GSK. Imidazolidine carboxamide derivatives as P2X7 modulators. US20100075968 (2010)
40. GSK. Thiadiazolidinedioxide P2X7 receptor antagonists. WO2011054947 (2011)
41. GSK. Pyrazole derivatives as P2X7 modulators. US20110046137 (2011)
42. GSK. 4-benzoyl-1-substituted-piperazin-2-one derivatives as P2X7 modulators. US20100311749 (2010)
43. GSK. 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyrazine derivatives as P2X7 modulators. US20120157436 (2012)
44. AstraZeneca. Quinoline derivatives 057. US8106073 (2012)
45. AstraZeneca. Compounds 679. US7964616 (2011)
46. Roche. Dihydropyrimidone amides as P2X7 modulators. US20110028502 (2011)
47. Roche. [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators. US20110071143 (2011)
48. Roche. Amido compounds. US20120149718 (2012)
49. Roche. Isoindolyl compounds. US20120157494 (2012)
50. Janssen Pharmaceutica. Quinoline or isoquinoline substituted P2X7 antagonists. US20110092481 (2011)
51. Janssen Pharmaceutica. 5,6,7,8,9,10-hexahydro-6,10-epimino[1,2,4]triazolo[4,3-a]azocines as P2X7 modulators. US20140275056 (2014)
52. Janssen Pharmaceutica. P2X7 modulators. US20140275120 (2014)
53. Janssen Pharmaceutica. [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators. US20140275096 (2014)
54. Actelion pharmaceuticals Ltd. Benzamide derivatives as P2X7 receptor antagonists. WO2012114268 (2012)
55. Actelion pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists. US20140163035 (2014)
56. Actelion pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists. US20150025075 (2015)
57. Actelion pharmaceuticals Ltd. Indole carboxamide derivatives as P2X7 receptor antagonists. WO2014097140 (2014)
58. H. LUNDBECK A/S. Heteroaryl amide analogues. US20120190680 (2012)
59. H. LUNDBECK A/S. Heteroaryl amide derivatives. US20120172366 (2013)
60. H. LUNDBECK A/S. Heteroaryl amide analogues as P2X7 antagonists. US8580812 (2013)
61. H. LUNDBECK A/S. Benzamides. WO2014057078 (2014)
62. H. LUNDBECK A/S. N-(2-(cyclic amine)ethyl)benzamide derivatives as P2X7 inhibitors. WO2014057080 (2014)
63. Renovis, INC. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof. US20100184802 (2010)
64. Renovis, INC. Novel compounds as P2X7 modulators and uses thereof. US20100022531 (2010)
65. Abbott. P2X7 receptor antagonists and methods of use. US7709469 (2010)
66. Abbott. Amino-tetrazoles analogues and methods of use. US7723367 (2010)
67. Nissan chemical industries, Ltd. Pyridazinone compounds and P2X7 receptor inhibitors. US20100286390 (2010)
68. Aventis Pharmaceuticals, Inc. Heterocyclic compounds as P2X7 ion channel blockers. US7741493 (2010)
69. Pfizer Product Inc. Benzamide and heteroarylamide as P2X7 receptor antagonists. EP1448535 (2011)
70. Schering corp. Triazolopyrazinones as P2X7 receptor antagonists. WO2012040048 (2012)
71. AXXAM S.P.A. Substituted thiazole or oxazole P2X7 receptor antagonists. WO2015118019 (2015)
72. Biosceptre International, Ltd. Hybridomas producing antibodies against nonfunctional P2X7 receptor. US20100105068 (2010)
73. Biosceptre International, Ltd. Combination therapy. US20150004179 (2015)
74. Abbott. P2X7 antagonists to treat affective disorders. US20110269708 (2011)
75. Royal College of Surgeons in Ireland. P2X7 antagonists as frontline or adjunctive treatment against status epilepticus. EP2604265 (2013)
76. Jackson Alexander. Imaging the central nervous system with purinergic P2X7 receptor binding agents. US20120034165 (2012)
77. Cornell Research Foundation, Inc. Purine receptor inhibition as a therapeutic strategy in spinal cord and brain. US7923448 (2011)
78. University Hospitals of Cleveland. P2X7:Inhibition of epithelial cancers and papillomas. US20140037576 (2014)
79. Claire Mitchell. Method for treatment of macular degeneration by modulating P2Y12 or P2X7 receptors. US20120264708 (2012)
80. Kaleko Michael. Therapies for disorders of the cornea and conjunctiva. US20140322193 (2014)
81. Astellas Pharma Inc. Therapeutic agent for fatty liver disease containing P2X7 receptor inhibitory substance as active ingredient. WO2012036193 (2012)
82. UCL Business Plc. P2X7 receptor agonist for use in preventing or treating kidney injury. WO2014174282 (2014)
83. Miras Portugal. Use of P2X7 receptor antagonists to promote axonal growth and ramification. WO2010018280 (2010)
84. Ali Z, Laurijssens B, Ostenfeld T, et al. Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects. Br J Clin Pharmacol. 2013;75(1):197–207.
85. Eser A, Colombel J-F, Rutgeerts P, et al. Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active crohn’s disease:a randomized placebo-controlled, double-blind, phase IIa study. Inflamm Bowel Dis. 2015;21(10):2247–2253.•• This article reported the results of phase IIa clinical study of Astra Zeneca’s P2X7R targeted new drug candidate, AZD-9056 in the patients with Crohn’s disease.
86. Kurashima Y, Amiya T, Nochi T, et al. Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat Commun. 2012;3:1034.• This article reported the roles of P2X7 receptor with intestinal inflammation in the patients with Crohn’s disease.
87. Sorge RE, Trang T, Dorfman R, et al. Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med. 2012;18(4):595–599.
88. Ying YL, Wei XH, Xu X-B, et al. Over-expression of P2X7 receptors in spinal glial cells contributes to the development of chronic postsurgical pain induced by skin/muscle incision and retraction (SMIR) in rats. Exp Neurol. 2014;261:836–843.
89. Bravo D, Maturana CJ, Pelissier T, et al. Interactions of pannexin 1 with NMDA and P2X7 receptors in central nervous system pathologies:Possible role on chronic pain. Pharmacol Res. 2015;101:86–93.
90. Takenouchi T, Sekiyama K, Sekigawa A, et al. P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. Arch Immunol Ther Exp (Warsz). 2010;58(2):91–96.
91. 11C]A-740003 as a novel tracer of neuroinflammation. J Labelled Comp Radiopharm. 2014;57(8):509–516.
92. Henshall DC, Engel T. P2X purinoceptors as a link between hyperexcitability and neuroinflammation in status epilepticus. Epilepsy Behav. 2015;49:8–12.
93. Iwata M, Ota KT, et al. Psychological stress activates the inflammasome via release of adenosine triphosphate and stimulation of the purinergic type 2x7 receptor. Biol Psychiatry. 2015;80(1):12–22.
94. Gao M, Wang M, Green MA, et al. Synthesis of [(11)C]GSK1482160 as a new PET agent for targeting P2X7 receptor. Bioorg Med Chem Lett. 2015;25(9):1965–1970.
95. Letavic MA, Lord B, Bischoff F, et al. Synthesis and pharmacological characterization of two novel, brain penetrating P2X7 antagonists. ACS Med Chem Lett. 2013;4(4):419–422.
96. Lord B, Ameriks MK, Wang Q, et al. A novel radioligand for the ATP-gated ion channel P2X7:[3H] JNJ-54232334. Eur J Pharmacol. 2015;765:551–559.
97. Rudolph DA, Alcazar J, et al. Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists. Bioorg Med Chem Lett. 2015;25(16):3157–3163.
98. Lord B, Aluisio L, et al. Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. J Pharmacol Exp Ther. 2014;351(3):628–641.
99. Chrovian CC, Soyode-Johnson A, et al. Novel phenyl-substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 antagonists with robust target engagement in rat brain. ACS Chem Neurosci. 2016;7(4):490–497.
100. Ziff J, Rudolph DA, Stenne B, et al. Substituted 5,6-(Dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-methanones as P2X7 antagonists. ACS Chem Neurosci. 2016;7(4):498–504.